This site is intended for Healthcare Professionals only.

NHS begins world’s largest trial of blood test for 50 types of cancer

Date:

Share post:

The NHS will today (September 13) begin the world’s largest trial of Grail Inc’s flagship Galleri blood test that can be used to detect more than 50 types of cancer before symptoms appear.

The Galleri test looks at the DNA in a patient’s blood to determine if any come from cancer cells.

Earlier diagnosis of cancers leads to dramatically increased survival rates.

The NHS said it wanted to recruit 140,000 volunteers in England to see how well the test worked as part of a randomised control trial.

Half of the participants will have their blood sample screened with the Galleri test right away.

“We need to study the Galleri test carefully to find out whether it can significantly reduce the number of cancers diagnosed at a late stage,” said Peter Sasieni, professor of cancer prevention at King’s College London.

“The test could be a game changer for early cancer detection and we are excited to be leading this important research.”

Lung cancer is by far the most common cause of cancer death in the United Kingdom, accounting for around a fifth of all cancer deaths. Lung, bowel, prostate and breast cancers account for 45 per cent of the United Kingdom’s cancer deaths, the NHS said.

U.S. life sciences company Illumina Inc said last month it had completed its $7.1 billion acquisition of Grail. Illumina said it will operate Grail separately from its existing business.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

ABPI: Increased pharma exports could boost GDP by £16.3 billion

ABPI urges political leaders to enhance healthcare and economic growth through strategic partnership The Association of the British Pharmaceutical...

The Importance Of Expanding Access To Dental Care For Rural And Undeserved Populations

In many rural areas and underserved neighborhoods, a critical issue is quietly emerging. Although often overlooked, its effects...

BGMA: More than 50% of UK generics face shortages without licensed alternatives

Brexit blamed by BGMA CE, Mark Samuels, as UK faces critical shortages in generic drug supply A recent report...

Paul Burden elected BGMA Vice-Chair, bringing 25 years of industry leadership

Veteran of off-patent sector to drive strategic engagement and patient access initiatives at BGMA The British Generic Manufacturers Association...